Project Grant 1831084

Cache DNA, Inc. was awarded a $255,819 National Science Foundation Technology, Innovation, and Partnerships Project Grant to develop a massively scalable storage solution for nucleic acids using barcoded polymer packets. The goal of the Phase I Small Business Innovation Research project is to establish a low-cost approach to maintaining the integrity of nucleic acids, including animal, bacterial, and viral genomes, at room temperature for decades without requiring energy-intensive freezing or...

The National Science Foundation awarded a $275,000 STTR Phase I grant to Inaedis, Inc. to develop an innovative method for the thermal stabilization of biopharmaceutical formulations. The project aims to establish a rapid room-temperature aerosol dehydration (RTAD) process that improves the stability of biologics, vaccines, and other pharmaceuticals, circumventing the need for a cold chain supply. This technology seeks to serve international markets by allowing the pharmaceutical industry to...

The Regents of the University of California, San Francisco (UCSF) received a $550,000 Project Grant award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop an advanced cryopreservation system for complex bioengineered tissues. The project aims to determine the thermodynamic and biological parameters needed for isochoric supercooling cryopreservation of three-dimensional tissues within a microgravity-optimized...

This National Science Foundation (NSF) Small Business Technology Transfer (STTR) Phase I grant, awarded under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program, provides $274,991 to Duravax Inc. to develop thermostable formulations of mRNA vaccines and therapeutics. The project aims to overcome the cold-chain limitations of current mRNA products by demonstrating the feasibility of storing mRNA APIs and mRNA-lipid nanoparticles at room temperature for extended periods. If...

Federal Project Grant Award Summary Cryocrate LLC received a $292,963 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), effective September 17, 2025, with completion targeted for August 31, 2028. The company is developing Odinsol, a novel polysaccharide-based cryopreservation medium designed to enhance the post-thaw viability and functionality of natural killer (NK) cells without toxic, cell-permeating cryoprotectants. This...

Nanoengineering Corporation received a $349,909 Project Grant from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) effective July 1, 2025, through June 30, 2027, to commercialize a viral vector sizing tool for gene therapy analytics. The company is developing NanoRanger, a portable benchtop instrument utilizing proprietary Electrospray Differential Mobility Analysis (ES-DMA) technology licensed from Yale University. This technology measures adeno-associated virus...

Federal Cooperative Agreement Summary Zaiput Flow Technologies LLC received a $1.25 million Phase II Small Business Innovation Research (SBIR) award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084), with an award date of June 15, 2025, and a completion deadline of May 31, 2027. The company is developing an innovative continuous crystallization device designed to address critical deficiencies in pharmaceutical manufacturing processes....

Federal Grant Award Summary The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded Massachusetts General Hospital $159,104 on February 13, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop and validate a novel microfluidic device technology for cryoprotective agent loading into therapeutic immune cells. The project, extending through August 31, 2027, focuses on designing and optimizing...

Federal Cooperative Agreement Summary Superior Nano LLC received a Phase II Small Business Innovation Research (SBIR) Cooperative Agreement valued at $1,247,672 from the National Science Foundation (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084), effective July 15, 2025, with a completion date of June 30, 2027. The award funds development of Dense Nanolipid Fluids (DNLFs) technology to create the first oral insulin delivery system for diabetes patients. Building on a...

This SBIR Phase I project, awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program, is focused on the development of a novel mammalian cell-based nano-biological coating for implantable medical devices. The goal is to address the critical health and economic burden associated with implant-related infections by reducing or eliminating them through the use of this biocompatible and antimicrobial nano-biological coating. The $305,000...